复方泽桑汤联合胸腺肽治疗系统性硬皮病的临床疗效观察

摘要

目的 回顾性分析复方泽桑汤联合胸腺肽治疗系统性硬皮病66例的临床疗效.方法 评估复方泽桑汤联合胸腺肽治疗系统性硬皮病66例半年后的疗效.结果 痊愈18例(27.3％),显效24例(36.4％),好转20例(30.3％),无效4例(6.1％),有效率为63.64％(42/66).结论 复方泽桑汤联合胸腺肽治疗系统性硬皮病疗效显著.%Objective To investigate the effect of Zesang polypharmacy combined with thymic peptide in treating systemic scleroderma (SSc). Methods 66 patients with SSc were treated with Zesang polypharmacy and thymic peptide for half a year, and than the score was measured to evaluate the treatment effect. Results The effective rate of combined treatment was 63.64% (42/66). Conclusion Zesang polypharmacy combined with thymic peptide seems to be effective in treating systemic scleroderma.